Answers are grounded in this paper and cite their sources.
Reports that peptide nanofiber and PAMP combinations improve CD4+ T cell functionality in lungs, suggesting enhanced immunity.
Vaccine adjuvants typically contain pathogen-associated molecular patterns (PAMPs) or danger-associated molecular patterns (DAMPs) that activate innate immune cells. The FDA’s approval of multiple PAMP-DAMP combinations for clinical use has generated increased momentum in this field in recent years. Here, we report the use of DAMP-inducing peptide nanofibers (PNFs) and CL429 (PAMP) combinations as subunit boosters for Bacille Calmette-Guérin (BCG). We demonstrate that pulmonary boosting with PNFs and CL429 enhances the lung-resident memory phenotype, effector cytokine profiles, and transcription factor bias of antigen-specific CD4+ T cell populations compared to PNFs alone. Importantly, the combination significantly improved the frequency of lung-specific memory T cells, which have been shown to provide superior protection compared to circulating memory T cells. Interestingly, the T helper (Th) subset profile was driven in part by the vaccination route, resulting in a Th17 bias via the mucosal route or a Th1 bias when delivered intravenously. We show that, following pulmonary administration, lung-resident antigen-presenting cells (APCs) efficiently internalize PNFs and upregulate crucial co-stimulatory markers that promote T cell priming and activation. Our findings suggest that heterologous booster vaccines composed of DAMP-inducing PNFs and PAMP combinations can engage both innate and adaptive immunity to generate memory T cells that protect against tuberculosis (TB) and potentially other respiratory diseases.
No takes yet. Share an insight, caveat, or question.
Files et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: